NDT Advance Access originally published online on March 15, 2005
Nephrology Dialysis Transplantation 2005 20(6):1110-1115; doi:10.1093/ndt/gfh771
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects
1 Albany Nephrology Pharmacy (ANephRx) Group, Albany College of Pharmacy, 2 Albany College of Medicine, Albany, NY, 3 Kidney Epidemiology and Cost Center, 6 University Renal Research and Education Association and 8 Division of Nephrology, University of Michigan, Ann Arbor, MI, 4 University of North Carolina-Chapel Hill, NC, 5 Metabolism Associates, New Haven, CT and 7 Nephrology Management Group, Sunnyvale, CA, USA
Correspondence and offprint requests to: George R. Bailie, MS, PharmD, PhD, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA. Email: bailieg{at}acp.edu
Background. Patients with chronic kidney disease (CKD) stages 2–5 are known to suffer numerous complications and co-morbidities associated with kidney disease. The medication prescription patterns in this population are not well understood. We report on prescription data collected as part of a multicentre longitudinal study in patients with CKD, with a focus on medications with cardiovascular or cardioprotective effects.
Methods. Patients were recruited from four academic nephrology centres in the USA, with patient recruitment from June 2000 to March 2002. Medication data were captured at the time of first enrolment into the study. Individual medications were classified into medication groups, and those with predominant cardioprotective effects or for prevention of progression of kidney disease (e.g. medications for treatment of anaemia, lipid-lowering agents, antihypertensives, statins, etc.) were recorded for analysis. Descriptive statistics were used for medication prescription according to baseline demographics and co-morbidities. Predictors of epoetin and iron use were determined by logistic regression adjusting for age, race, sex, diabetes, glomerular filtration rate (GFR), haemoglobin and serum albumin.
Results. Medication data were available for 619 patients with stages 2–5 CKD. Patients were 60.6±16.0 years of age, and were prescribed 8±4 (range 1–28) medications. Overall, the proportion of patients prescribed different classes of medications included epoetin (20%), intravenous iron (13%), HMG-CoA reductase inhibitors (16%), angiotensin-converting enzyme (ACE) inhibitors (44%), angiotensin receptor blockers (13%), ß-blockers (46%), calcium channel blockers (52%) and aspirin (37%). There was a low use of epoetin (45%) and iron (20%) in patients with anaemia. Only 24% of patients with coronary artery disease were prescribed statins, and ACE inhibitors and angiotensin receptor blockers were used in only 58 and 23% of diabetic patients with proteinuria. Positive predictors of epoetin and iron therapy included white race and diabetes. Higher GFR and higher serum albumin were associated with lower odds of being prescribed epoetin. White race and diabetics were more likely to be prescribed iron.
Conclusions. This study provides an overview of prescription practices in a cohort of CKD patients. Substantial underutilization of certain classes of cardioprotective medications is apparent, and systematic educational efforts in this direction may well prove worthwhile to impact outcomes.
Keywords: chronic kidney disease; medication use; prescription patterns; RRI-CKD study
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Thilly, S. Boini, M. Kessler, S. Briancon, and L. Frimat Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: data from the AVENIR study (AVantagE de la Nephroprotection dans l'Insuffisance Renale) Nephrol. Dial. Transplant., March 1, 2009; 24(3): 934 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Minutolo, P. Chiodini, B. Cianciaruso, A. Pota, V. Bellizzi, D. Avino, S. Mascia, S. Laurino, V. Bertino, G. Conte, et al. Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ruggenenti and G. Remuzzi Kidney Failure Stabilizes after a Two-Decade Increase: Impact on Global (Renal and Cardiovascular) Health Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 146 - 150. [Full Text] [PDF]
|
|
|
|
|
|
C. Jones-Burton, S. L. Seliger, J. Brown, L. Stackiewicz, V. Doren Hsu, and J. C. Fink Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2739 - 2745. [Abstract] [Full Text] [PDF]
|
|